Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PARG covalent inhibitor (Satya Pharma Innovations)
- Development stage
- Preclinical
- Lead developer
- Satya Pharma Innovations
- Modality
- Small Molecules
01
Overview
This is a preclinical-stage covalent small molecule inhibitor of poly(ADP-ribose) glycohydrolase (PARG) being developed by Satya Pharma Innovations. The compound functions by covalently binding to PARG, an enzyme responsible for the degradation of poly(ADP-ribose) (PAR) polymers. Inhibition of PARG leads to the toxic accumulation of PAR chains, which disrupts the DNA damage repair (DDR) cycle and ultimately triggers apoptosis in cancer cells. This differentiated approach aims to provide sustained pharmacodynamic effects compared to reversible inhibitors. The program is currently focused on the treatment of breast and ovarian cancers.
- Other names
- PARG Covalent Inhibitor
02
Targets
PARG (Poly(ADP-ribose) glycohydrolase)
Beyond the preview
Go deeper on PARG covalent inhibitor (Satya Pharma Innovations).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PARG covalent inhibitor (Satya Pharma Innovations).